Inhibitor Therapeutics Offers a Promising Pipeline and an Experienced Management Team
Inhibitor Therapeutics (OTCQB: INTI), a Biopharmaceutical Company focussed on addressing the unmet medical needs in the field of cancerous and non-cancerous proliferation disorders, announced the receipt of an Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for traconazole, intended for...
